ARC-02 + Rituximab for Non-Hodgkin's Lymphoma

(ABLATE-101 Trial)

This trial tests a new treatment called ARC-02 for people with B-cell Non-Hodgkin's Lymphoma, a type of blood cancer. The study explores the safety and effectiveness of ARC-02 when used alone or with Rituximab, a monoclonal antibody therapy. Researchers aim to understand how the body reacts to different doses and whether the treatment can help control the cancer. Participants should have a diagnosis of B-cell Non-Hodgkin's Lymphoma and have tried at least two other treatments without success. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new therapy.

The trial requires that you stop taking chemotherapy, radiotherapy, small molecule, investigational, and biologic agents at least 28 days before starting the study. It doesn't specify about other medications, so you should discuss your current medications with the study team.

Earlier research has shown that ARC-02 has a promising safety profile in lab studies. This treatment is being tested for certain blood cancers. Although human studies provide limited information, early tests suggest it might be well-tolerated.

When combined with rituximab, a drug often used for similar conditions, more safety information becomes available. Rituximab alone is generally well-tolerated. Some patients have experienced mild to moderate side effects, such as reactions during drug administration. Severe reactions are rare but can occur, especially during the first treatment.

ARC-02 is unique because it offers a novel approach to treating Non-Hodgkin's Lymphoma by potentially targeting cancer cells more precisely. Unlike standard treatments like R-CHOP or Rituximab alone, ARC-02 may provide a different mechanism of action, enhancing the body's ability to fight the disease. Researchers are particularly excited about its use in combination with Rituximab, as this combination could amplify the effectiveness of treatment by leveraging both ARC-02's new mechanism and Rituximab's established ability to target B-cell malignancies. This combined approach might lead to better outcomes and fewer side effects than traditional therapies.

Research has shown that ARC-02 could be a promising treatment for non-Hodgkin's lymphoma. Early studies suggest it has good potential, but its effectiveness in people is still under investigation. In this trial, some participants will receive ARC-02 alone, while others will receive it in combination with rituximab, a well-known treatment. Studies have indicated that combining rituximab with other treatments can lead to high success rates, sometimes up to 92%. This suggests that using ARC-02 with rituximab might be a strong option for treating non-Hodgkin's lymphoma.⁶⁷⁸⁹¹⁰